Trial Profile
A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REALIST
- 21 Jun 2019 Planned End Date changed from 30 May 2023 to 30 Mar 2024.
- 21 Jun 2019 Planned primary completion date changed from 7 Oct 2019 to 30 Sep 2023.
- 21 Jun 2019 Planned initiation date changed from 15 Oct 2018 to 1 Sep 2019.